Clinical Trial Update: Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial update describes evaluation of PD-1 inhibitors after CD30 CAR T-cell therapy in patients with relapsed or refractory Hodgkin lymphoma, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• OPDIVO (nivolumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING